Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology Review uri icon

Overview

MeSH Major

  • Anemia
  • Antineoplastic Agents
  • Medical Oncology
  • Neoplasms

abstract

  • Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

publication date

  • May 2012

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 22570293

Additional Document Info

start page

  • 628

end page

  • 53

volume

  • 10

number

  • 5